Intas Pharmaceuticals Expands Their Reach with UDENYCA Acquisition

Deal News | Aug 07, 2025 | PR Newswire Cision Accord Healthcare

Intas Pharmaceuticals, in partnership with its subsidiaries operating under the Accord brand, has acquired UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc., cementing its status as a leader in the global biosimilar market. The acquisition strengthens Accord's presence in the U.S. and international markets, enhancing its product offerings and facilitating the addition of key talent from Coherus. Accord BioPharma, Intas's U.S. specialty business, will continue the commercialization of UDENYCA to mitigate infection in patients treated with myelosuppressive cancer therapies and improve patient flexibility with varied administration options. Since launch, UDENYCA has treated over 300,000 patients worldwide. The acquisition not only expands Intas's biosimilar portfolio but also aligns with its commitment to expanding patient access to healthcare globally.

Sectors

  • Pharmaceuticals and Biotechnology
  • Healthcare

Geography

  • India – Intas Pharmaceuticals is based in Ahmedabad, India, and plays a pivotal role in this transaction.
  • United States – The acquisition involves Accord BioPharma, a U.S. specialty division, and impacts the commercialization of UDENYCA in the U.S. market.

Industry

  • Pharmaceuticals and Biotechnology – The article focuses on Intas Pharmaceuticals' acquisition of UDENYCA, a major step in expanding their biosimilar portfolio and strengthening their position in the pharmaceutical industry.
  • Healthcare – The acquisition impacts the healthcare sector as it involves expanding access to critical biosimilar treatments for patients globally.

Financials

    Participants

    NameRoleTypeDescription
    Intas PharmaceuticalsAcquirerCompanyA leading pharmaceutical company based in India, acquiring UDENYCA to expand its biosimilar portfolio.
    Accord BioPharmaAcquirerCompanyThe U.S. specialty business of Intas Pharmaceuticals involved in the commercialization of UDENYCA.
    Coherus BioSciences, Inc.VendorCompanyA biopharmaceutical company based in the U.S. that was the previous owner of UDENYCA.
    Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.Legal AdvisorCompanyProvided legal counsel to Accord and Intas regarding the acquisition.
    Chrys KokinoU.S. President of Accord BioPharmaPersonCommented on the strategic significance of the UDENYCA acquisition for Accord BioPharma.
    Paul TredwellEMENA Executive Vice-President of AccordPersonHighlighted Accord's strategic goal to become a leading supplier of pegfilgrastim.
    Binish ChudgarChairman and Managing Director of Intas PharmaceuticalsPersonExpressed commitment to improving patient access to high-quality treatments.